RespireRx Pharmaceuticals Management
Management criteria checks 4/4
RespireRx Pharmaceuticals' El consejero delegado es Arnold Lippa , nombrado en Aug 2015, tiene un mandato de 8.33 años. la remuneración anual total es $339.60K , compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente 3.14% de las acciones de la empresa, por valor de $11.06K . La antigüedad media del equipo directivo y del consejo de administración es de 9.2 años y 10 años respectivamente.
Key information
Arnold Lippa
Chief executive officer
US$339.6k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 8.7yrs |
| CEO ownership | 1.5% |
| Management average tenure | 9.5yrs |
| Board average tenure | 9.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$4m |
| Dec 31 2022 | US$340k | US$340k | -US$4m |
| Sep 30 2022 | n/a | n/a | -US$4m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$340k | US$340k | -US$4m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$340k | US$340k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$340k | US$340k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$2m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | US$340k | US$340k | -US$3m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$3m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$614k | US$340k | -US$4m |
Compensación vs. Mercado: Arnold($USD339.60K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD740.57K).
Compensación vs. Ingresos: Arnoldha sido coherente con los resultados de la empresa en el último año.
CEO
Arnold Lippa (76 yo)
8.7yrs
Tenure
US$339,600
Compensation
Dr. Arnold S. Lippa, Ph D., has been an Executive Chairman of RespireRx Pharmaceuticals Inc., since March 22, 2013 and its Chief Scientific Officer since August 19, 2015 and has been its Interim President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.7yrs | US$339.60k | 1.48% $ 10.3k | |
| Senior VP | 11.1yrs | US$321.60k | 1.37% $ 9.6k | |
| Senior Vice President of Research & Development | 9.5yrs | US$199.86k | 0.000080% $ 0.6 | |
| Senior Vice President of Pre-Clinical Product Development | 3.6yrs | no data | 0% $ 0 | |
| Controller | 10.8yrs | no data | 0.27% $ 1.9k |
9.5yrs
Average Tenure
64.5yo
Average Age
Equipo directivo experimentado: RSPIEl equipo directivo de la empresa es veterano y experimentado (9.2 años de antigüedad media).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.1yrs | US$339.60k | 1.48% $ 10.3k | |
| Senior VP | 11.1yrs | US$321.60k | 1.37% $ 9.6k | |
| Independent Director | 1.1yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 9.6yrs | no data | no data | |
| Director | less than a year | no data | no data |
9.6yrs
Average Tenure
75yo
Average Age
Junta con experiencia: La junta directiva de RSPI se considera experimentada (9.3 años de antigüedad promedio).